Drug Trial Radar · NCT02938299
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
214
Planned (sponsor's estimate)
Start
Jul 1, 2016
Primary completion
Oct 2024
Study completion Dec 2028
Sponsor
- Lead sponsor
- Philogen S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
Conditions
- Malignant Melanoma
Interventions
L19IL2 + L19TNFDrug
Mixture of L19IL2 and L19TNF once weekly
SurgeryProcedure
Surgical resection of melanoma tumor lesions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survival (RFS) rateTime frame: 1 year after randomization
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital de la Timone
Marseille, France
Hôpital Universitaire de Nantes
Nantes, France
Institut Gustave Roussy
Villejuif, France
Klinik für Dermatologie und Allergologie, Universitätsklinikum Augsburg
Augsburg, Germany
Klinik für Dermatologie, Medizinische Fakultät Universitätsklinikum Essen
Essen, Germany
Klinik und Polyklinik für Dermatologie, Universitätsklinikum Regensburg
Regensburg, Germany
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Dresden, Dresden, Germany
Hauttumorzentrum Hannover (HTZH)
Hanover, Hannover, Germany
Heidelberg University Hospital
Heidelberg, Heidelberg, Germany
Kiel University Hospital
Kiel, Kiel, Germany
Leipzig University Hospital
Leipzig, Leipzig, Germany
Charité Campus Mitte (CCM)
Berlin, State of Berlin, Germany
Tübingen University Hospital
Tübingen, Tübingen, Germany
Fondazione IRCCS Istituto Nazionale dei Tumori
Naples, Italy
AOU Senese
Siena, Italy
ASUGI Trieste
Trieste, Italy
AOU Città della Salute e della Scienza
Turin, Italy
IRCCS A.O.U. San Martino - IST
Genova, Genova, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milan, Italy
Istituto Oncologico Veneto, IRCCS
Padova, Padova, Italy
Medgart Centrum Medyczne
Gdansk, Poland
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.